Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MSN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MSN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MSN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MSN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MSN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MSN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MSN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000188513 | Lung | AIS | endothelial cell development | 16/1849 | 64/18723 | 3.78e-04 | 6.61e-03 | 16 |
GO:190165413 | Lung | AIS | response to ketone | 34/1849 | 194/18723 | 6.76e-04 | 1.01e-02 | 34 |
GO:003508811 | Lung | AIS | establishment or maintenance of apical/basal cell polarity | 13/1849 | 49/18723 | 7.13e-04 | 1.04e-02 | 13 |
GO:006124511 | Lung | AIS | establishment or maintenance of bipolar cell polarity | 13/1849 | 49/18723 | 7.13e-04 | 1.04e-02 | 13 |
GO:003238612 | Lung | AIS | regulation of intracellular transport | 52/1849 | 337/18723 | 7.89e-04 | 1.11e-02 | 52 |
GO:004873213 | Lung | AIS | gland development | 63/1849 | 436/18723 | 1.34e-03 | 1.66e-02 | 63 |
GO:19029461 | Lung | AIS | protein localization to early endosome | 5/1849 | 10/18723 | 1.54e-03 | 1.82e-02 | 5 |
GO:00611621 | Lung | AIS | establishment of monopolar cell polarity | 8/1849 | 24/18723 | 1.54e-03 | 1.82e-02 | 8 |
GO:000315812 | Lung | AIS | endothelium development | 25/1849 | 136/18723 | 1.67e-03 | 1.90e-02 | 25 |
GO:190382913 | Lung | AIS | positive regulation of cellular protein localization | 43/1849 | 276/18723 | 1.77e-03 | 2.01e-02 | 43 |
GO:003253513 | Lung | AIS | regulation of cellular component size | 56/1849 | 383/18723 | 1.83e-03 | 2.05e-02 | 56 |
GO:00613391 | Lung | AIS | establishment or maintenance of monopolar cell polarity | 8/1849 | 25/18723 | 2.07e-03 | 2.27e-02 | 8 |
GO:009892712 | Lung | AIS | vesicle-mediated transport between endosomal compartments | 11/1849 | 43/18723 | 2.47e-03 | 2.55e-02 | 11 |
GO:00226126 | Lung | AIS | gland morphogenesis | 22/1849 | 118/18723 | 2.55e-03 | 2.62e-02 | 22 |
GO:003238812 | Lung | AIS | positive regulation of intracellular transport | 33/1849 | 202/18723 | 2.67e-03 | 2.70e-02 | 33 |
GO:004519711 | Lung | AIS | establishment or maintenance of epithelial cell apical/basal polarity | 11/1849 | 44/18723 | 3.01e-03 | 2.97e-02 | 11 |
GO:0035089 | Lung | AIS | establishment of apical/basal cell polarity | 7/1849 | 22/18723 | 4.07e-03 | 3.65e-02 | 7 |
GO:004544612 | Lung | AIS | endothelial cell differentiation | 21/1849 | 118/18723 | 5.54e-03 | 4.71e-02 | 21 |
GO:190165511 | Lung | AIS | cellular response to ketone | 18/1849 | 96/18723 | 5.64e-03 | 4.76e-02 | 18 |
GO:002260423 | Lung | AAH | regulation of cell morphogenesis | 30/613 | 309/18723 | 1.18e-07 | 6.77e-05 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MSN | SNV | Missense_Mutation | | c.1189N>A | p.Glu397Lys | p.E397K | P26038 | protein_coding | tolerated(0.32) | possibly_damaging(0.61) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
MSN | SNV | Missense_Mutation | | c.1678C>T | p.Arg560Cys | p.R560C | P26038 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MSN | SNV | Missense_Mutation | | c.1507N>T | p.Arg503Cys | p.R503C | P26038 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MSN | SNV | Missense_Mutation | | c.855N>A | p.Met285Ile | p.M285I | P26038 | protein_coding | tolerated(0.23) | benign(0.029) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MSN | SNV | Missense_Mutation | rs753856958 | c.659N>G | p.Val220Gly | p.V220G | P26038 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MSN | SNV | Missense_Mutation | rs770945316 | c.299G>A | p.Arg100His | p.R100H | P26038 | protein_coding | tolerated(0.58) | benign(0.068) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
MSN | SNV | Missense_Mutation | novel | c.1034A>G | p.Glu345Gly | p.E345G | P26038 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
MSN | insertion | In_Frame_Ins | novel | c.342_343insCTCACCTTACCCTTACCCTCCACTTGCATCCTTCTCCCAAAAAAC | p.Asp114_Ile115insLeuThrLeuProLeuProSerThrCysIleLeuLeuProLysAsn | p.D114_I115insLTLPLPSTCILLPKN | P26038 | protein_coding | | | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
MSN | SNV | Missense_Mutation | novel | c.322N>A | p.Glu108Lys | p.E108K | P26038 | protein_coding | tolerated(0.09) | possibly_damaging(0.47) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MSN | SNV | Missense_Mutation | rs778459733 | c.835N>T | p.Arg279Trp | p.R279W | P26038 | protein_coding | deleterious(0.03) | possibly_damaging(0.598) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |